Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody

Frontiers in Immunology

Mengqi Yuan¹  Pinghuang Liu¹  Juan Wang²  Yang Yang³  Kai Deng⁴  Xiangyu Chen⁵  Bo Zhu⁵  Jianfang Tang⁷  Zhirong Li⁷  Qin Tian⁷  Yaxing Hao⁷  Yao Lin⁷  Zhiwei Pan⁷  Shuai Yue⁷  Li Hu⁷  Yifei Wang⁷  Li Wang⁷  Lifan Xu⁷  Jing Zhou⁷  Lilin Ye⁷  Qizhao Huang⁷  Leiqiong Gao⁷ 

[1] College of Veterinary Medicine, China Agricultural University, Beijing, China;Department of Emergency Medicine, Southwest Hospital, Third Military Medical University, Chongqing, China;Department of Stomatology, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing, China;Infectious Diseases Institute, Guangzhou Eighth People’s Hospital, Guangzhou Medical University, Guangzhou, China;Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, China;Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China;Institute of Immunology, Third Military Medical University, Chongqing, China;

关键词: COVID-19;    SARS-CoV-2 variants;    neutralizing mAb;    convalescent sera;    antibody response;   

DOI  :  10.3389/fimmu.2021.751584

来源: DOAJ

【 摘 要 】

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel coronavirus disease (COVID-19). Though vaccines and neutralizing monoclonal antibodies (mAbs) have been developed to fight COVID-19 in the past year, one major concern is the emergence of SARS-CoV-2 variants of concern (VOCs). Indeed, SARS-CoV-2 VOCs such as B.1.1.7 (UK), B.1.351 (South Africa), P.1 (Brazil), and B.1.617.1 (India) now dominate the pandemic. Herein, we found that binding activity and neutralizing capacity of sera collected from convalescent patients in early 2020 for SARS-CoV-2 VOCs, but not non-VOC variants, were severely blunted. Furthermore, we observed evasion of SARS-CoV-2 VOCs from a VH3-30 mAb 32D4, which was proved to exhibit highly potential neutralization against wild-type (WT) SARS-CoV-2. Thus, these results indicated that SARS-CoV-2 VOCs might be able to spread in convalescent patients and even harbor resistance to medical countermeasures. New interventions against these SARS-CoV-2 VOCs are urgently needed.

【 授权许可】

Unknown